Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
Abstract Background Though often overlooked, calming patients and increasing their life engagement are key factors in the treatment of
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy
Highlights • This study evaluated chronobiologic sleep parameters in major depressive disorder. • Nine depressed patients received open-label adjunctive
Effect of Brexpiprazole on Prolactin and Sexual Functioning. An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
Abstract Purpose/Background Evidence supports use of adjunctive atypical antipsychotics in major depressive disorder (MDD). Impaired sexual functioning is common
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies
Abstract Objective: To analyze the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with major depressive
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies
Abstract Background: There is a need for effective, safe and well-tolerated pharmacotherapies for patients with major depressive disorder (MDD)
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Abstract Background Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
Abstract Objective Episodes of major depressive disorder (MDD) characterized by high levels of anxiety symptoms are less likely to
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
Abstract Objectives The objective of this study was to evaluate the long‐term safety and tolerability of flexible‐dose brexpiprazole adjunct
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Implications/conclusions: Differences in tolerability profiles regarding activation and sedation have implications in terms of selecting the optimal antipsychotic
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
Abstract Objective: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD).
Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study
Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator. We evaluated the effects of adjunctive treatment with brexpiprazole on sleep disturbances
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment
Highlights • Many patients with MDD experience symptoms that impair functioning and productivity. • Brexpiprazole+ADT was studied in young
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
Abstract Background: Approximately 50% of patients with major depressive disorder do not respond adequately to their antidepressant treatment, underscoring
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials
Highlights • Brexpiprazole is an adjunctive therapy for treatment of MDD. • Anxiety symptoms are prevalent in MDD and
Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Abstract Objective: To summarize efficacy data from two phase 2 and two phase 3 short-term, multicenter, randomized, double-blind, placebo-controlled
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
Abstract Background Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult‐to‐treat patient. Brexpiprazole is a serotonin–dopamine
Mechanism of action of brexpiprazole: comparison with aripiprazole
Abstract Brexpiprazole is a new therapeutic agent that was recently approved for the treatment of schizophrenia and for the
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Abstract Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
Abstract Background Though often overlooked, calming patients and increasing their life engagement are key factors in the treatment of major depressive disorder (MDD).
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy
Highlights • This study evaluated chronobiologic sleep parameters
Effect of Brexpiprazole on Prolactin and Sexual Functioning. An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
Abstract Purpose/Background Evidence supports use of adjunctive atypical
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies
Abstract Objective: To analyze the effect of adjunctive brexpiprazole
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies
Abstract Background: There is a need for effective,
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Abstract Background Long-term treatment is recommended in major
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
Abstract Objective Episodes of major depressive disorder (MDD)
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
Abstract Objectives The objective of this study was
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Implications/conclusions: Differences in tolerability profiles regarding activation
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
Abstract Objective: To evaluate the effects of adjunctive brexpiprazole
Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study
Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator. We
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment
Highlights • Many patients with MDD experience symptoms
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
Abstract Background: Approximately 50% of patients with major
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials
Highlights • Brexpiprazole is an adjunctive therapy for
Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Abstract Objective: To summarize efficacy data from two
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
Abstract Background Major depressive disorder (MDD) with concurrent
Mechanism of action of brexpiprazole: comparison with aripiprazole
Abstract Brexpiprazole is a new therapeutic agent that
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Abstract Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug